Zenas BioPharma, Inc. Investing Cash Flow
Zenas BioPharma, Inc. (ZBIO) reported Investing Cash Flow of -$256.09 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-13.
Financial Statements › Cash Flow › Investing Activities
us-gaap:NetCashProvidedByUsedInInvestingActivities · last filed 2026-08-13
- Zenas BioPharma, Inc. net cash provided by (used in) investing activities for the quarter ending 2026-06-30 was -$287.70M.
- Zenas BioPharma, Inc. net cash provided by (used in) investing activities for the quarter ending 2026-03-31 was $31.61M.
- Zenas BioPharma, Inc. net cash provided by (used in) investing activities for the quarter ending 2025-12-31 was -$93.36M.
- Zenas BioPharma, Inc. net cash provided by (used in) investing activities for the quarter ending 2025-09-30 was $40.04M.
- Zenas BioPharma, Inc. net cash provided by (used in) investing activities for fiscal 2025 was -$251.89M.
- Zenas BioPharma, Inc. net cash provided by (used in) investing activities for fiscal 2024 was -$30.55M.
- Zenas BioPharma, Inc. net cash provided by (used in) investing activities for fiscal 2023 was -$17.00K.
| Period end | Net Cash Provided by (Used in) Investing Activities 3 month | Net Cash Provided by (Used in) Investing Activities 6 month | Net Cash Provided by (Used in) Investing Activities 9 month | Net Cash Provided by (Used in) Investing Activities 12 month |
|---|---|---|---|---|
| 2026-06-30 | -$287.70M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-13 | -$256.09M 10-Q · filed 2026-08-13 | -$349.46M derived: sum of 3 quarters · filed 2026-08-13 | -$309.41M derived: sum of 4 quarters · filed 2026-08-13 |
| 2026-03-31 | $31.61M 10-Q · filed 2026-05-13 | -$61.75M derived: sum of 2 quarters · filed 2026-05-13 | -$21.71M derived: sum of 3 quarters · filed 2026-05-13 | -$134.00M derived: sum of 4 quarters · filed 2026-08-13 |
| 2025-12-31 | -$93.36M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-16 | -$53.32M derived: sum of 2 quarters · filed 2026-03-16 | -$165.61M derived: sum of 3 quarters · filed 2026-08-13 | -$251.89M 10-K · filed 2026-03-16 |
| 2025-09-30 | $40.04M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-12 | -$72.25M derived: sum of 2 quarters · filed 2026-08-13 | -$158.52M 10-Q · filed 2025-11-12 | -$162.26M derived: sum of 4 quarters · filed 2026-08-13 |
| 2025-06-30 | -$112.29M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-13 | -$198.56M 10-Q · filed 2026-08-13 | -$202.30M derived: sum of 3 quarters · filed 2026-08-13 | -$229.06M derived: sum of 4 quarters · filed 2026-08-13 |
| 2025-03-31 | -$86.27M 10-Q · filed 2026-05-13 | -$90.01M derived: sum of 2 quarters · filed 2026-05-13 | -$116.77M derived: sum of 3 quarters · filed 2026-05-13 | -$116.80M derived: sum of 4 quarters · filed 2026-05-13 |
| 2024-12-31 | -$3.73M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-16 | -$30.50M derived: sum of 2 quarters · filed 2026-03-16 | -$30.53M derived: sum of 3 quarters · filed 2026-03-16 | -$30.55M 10-K · filed 2026-03-16 |
| 2024-09-30 | -$26.76M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-12 | -$26.80M derived: sum of 2 quarters · filed 2025-11-12 | -$26.82M 10-Q · filed 2025-11-12 | |
| 2024-06-30 | -$35.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-12 | -$57.00K 10-Q · filed 2025-08-12 | ||
| 2024-03-31 | -$22.00K 10-Q · filed 2025-05-15 | |||
| 2023-12-31 | -$17.00K 10-K · filed 2025-03-11 |